BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

Summary by AI BETAClose X

BioNTech SE's Annual General Meeting saw shareholders approve all agenda items, with 92% of share capital represented, including the expansion of the Supervisory Board from six to eight members with the election of Prof. Iris Löw-Friedrich and Susanne Schaffert, bringing additional expertise in clinical development, oncology, and commercialization to support the company's focus on its late-stage oncology pipeline. The mandates of existing Supervisory Board members Helmut Jeggle, Prof. Anja Morawietz, and Prof. Rudolf Staudigl were also extended, and Helmut Jeggle was elected Chairman of the Supervisory Board.

Disclaimer*

UK 100

Latest directors dealings